Korean J Gastroenterol.  2025 Jan;85(1):11-21. 10.4166/kjg.2024.135.

Relationship between Abnormal Lipid Metabolism and Gallstone Formation

• Li X
• Yin X
• Xu J
• Geng L
• Liu Z

• KMID: 2565010
• DOI: http://doi.org/10.4166/kjg.2024.135

Abstract

Cholelithiasis is a common biliary system disease with a high incidence worldwide. Abnormal lipid metabolism has been shown to play a key role in the mechanism of gallstones. Therefore, recent research literature on the genes, proteins, and molecular substances involved in lipid metabolism during the pathogenesis of gallstones has been conducted. This study aimed to determine the role of lipid metabolism in the pathogenesis of gallstones and provide insights for future studies using previous research in genomics, metabolomics, transcriptomics, and other fields.

Keyword

Gallstones; Lipid metabolism; Triglycerides; Phospholipids; Metabolomics

Figure

• 

  Fig. 1 In vivo synthesis and metabolic pathways of cholesterol.

• 

  Fig. 2 Key enzymes for phospholipid synthesis and metabolism in vivo.

• 

  Fig. 3 Effects of MDR3 mutations on phospholipid transport on the membrane of hepatic tubular cells.

• 

  Fig. 4 Pathway of TCA cycle in the formation of gallstones.

• 

  Fig. 5 Positions and roles of CD36, APOA-1, SR-BI, and CYP7A1 in the KEGG pathway of cholesterol synthesis.

Reference

1. Lammert F, Gurusamy K, Ko CW, et al. 2016; Gallstones. Nat Rev Dis Primers. 2:16024. DOI: 10.1038/nrdp.2016.24.

2. Chen CH, Huang MH, Yang JC, et al. 2006; Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey. J Gastroenterol Hepatol. 21:1737–1743. DOI: 10.1111/j.1440-1746.2006.04381.x. PMID: 16984599.

3. Qiao T, Ma RH, Luo XB, Yang LQ, Luo ZL, Zheng PM. 2013; The systematic classification of gallbladder stones. PLoS One. 8:e74887. DOI: 10.1371/journal.pone.0074887. PMID: 24124459. PMCID: PMC3790764.

4. Tazuma S. 2006; Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intra-hepatic). Best Pract Res Clin Gastroenterol. 20:1075–1083. DOI: 10.1016/j.bpg.2006.05.009. PMID: 17127189.

5. Schafmayer C, Hartleb J, Tepel J, et al. 2006; Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. BMC Gastroenterol. 6:36. DOI: 10.1186/1471-230X-6-36. PMID: 17121681. PMCID: PMC1664574.

6. Portincasa P, Moschetta A, Palasciano G. 2006; Cholesterol gallstone disease. Lancet. 368:230–239. DOI: 10.1016/S0140-6736(06)69044-2. PMID: 16844493.

7. Chen L, Yang H, Li H, He C, Yang L, Lv G. 2022; Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study. Hepatology. 75:785–796. DOI: 10.1002/hep.32183. PMCID: PMC9300195.

8. Klass DM, Lauer N, Hay B, Kratzer W, Fuchs M. EMIL Study Group. 2007; Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation. Am J Gastroenterol. 102:2482–2487. DOI: 10.1111/j.1572-0241.2007.01430.x. PMID: 17640319.

9. Reshetnyak VI. 2012; Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol. 4:18–34. DOI: 10.4254/wjh.v4.i2.18. PMID: 22400083. PMCID: PMC3295849.

10. Itani M, Dubinsky TJ. 2017; Physical chemistry of bile: Detailed pathogenesis of cholelithiasis. Ultrasound Q. 33:229–236. DOI: 10.1097/RUQ.0000000000000287. PMID: 28350710.

11. Santana-Gálvez J, Cisneros-Zevallos L, Jacobo-Velázquez DA. 2017; Chlorogenic acid: Recent advances on its dual role as a food additive and a nutraceutical against metabolic syndrome. Molecules. 22:358. DOI: 10.3390/molecules22030358. PMID: 28245635. PMCID: PMC6155416.

12. Worthington HV, Hunt LP, McCloy RF, Ubbink JB, Braganza JM. 2004; Dietary antioxidant lack, impaired hepatic glutathione reserve, and cholesterol gallstones. Clin Chim Acta. 349:157–165. DOI: 10.1016/j.cccn.2004.06.022. PMID: 15469869.

13. Fremont-Rahl JJ, Ge Z, Umana C, et al. 2013; An analysis of the role of the indigenous microbiota in cholesterol gallstone pathogenesis. PLoS One. 8:e70657. DOI: 10.1371/journal.pone.0070657. PMID: 23923015. PMCID: PMC3726617.

14. Alves-Bezerra M, Cohen DE. 2017; Triglyceride metabolism in the liver. Compr Physiol. 8:1–8. DOI: 10.1002/cphy.c170012. PMCID: PMC6376873.

15. Tamura Y, Sesaki H, Endo T. 2014; Phospholipid transport via mitochondria. Traffic. 15:933–945. DOI: 10.1111/tra.12188. PMID: 24954234. PMCID: PMC4140972.

16. DeBose-Boyd RA. 2018; Significance and regulation of lipid metabolism. Semin Cell Dev Biol. 81:97. DOI: 10.1016/j.semcdb.2017.12.003. PMID: 29246858.

17. Jones JG. 2016; Hepatic glucose and lipid metabolism. Diabetologia. 59:1098–1103. DOI: 10.1007/s00125-016-3940-5. PMID: 27048250.

18. Cortes VA, Busso D, Maiz A, Arteaga A, Nervi F, Rigotti A. 2014; Physiological and pathological implications of cholesterol. Front Biosci (Landmark Ed). 19:416–428. DOI: 10.2741/4216. PMID: 24389193.

19. Luo J, Yang H, Song BL. 2020; Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 21:225–245. DOI: 10.1038/s41580-019-0190-7. PMID: 31848472.

20. Cholesterol absorption versus cholesterol synthesis in man. Nutr Rev. 1970; 28:11–15. DOI: 10.1111/j.1753-4887.1970.tb06143.x. PMID: 4906653.

21. Márk L, Paragh G. 2007; Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption. Orv Hetil. 148:627–632. DOI: 10.1556/oh.2007.28065. PMID: 17403635.

22. Schroepfer GJ Jr. 2000; Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 80:361–554. DOI: 10.1152/physrev.2000.80.1.361. PMID: 10617772.

23. Phillips MC. 2014; Molecular mechanisms of cellular cholesterol efflux. J Biol Chem. 289:24020–24029. DOI: 10.1074/jbc.R114.583658. PMID: 25074931. PMCID: PMC4148835.

24. Zhang Q, Ke Y, Hong H. 2022; HDL and Lipid Metabolism. Adv Exp Med Biol. 1377:49–61. DOI: 10.1007/978-981-19-1592-5_4. PMID: 35575920.

25. Bilotta MT, Petillo S, Santoni A, Cippitelli M. 2020; Liver X receptors: Regulators of cholesterol metabolism, inflammation, autoimmunity, and cancer. Front Immunol. 11:584303. DOI: 10.3389/fimmu.2020.584303. PMID: 33224146. PMCID: PMC7670053.

26. Nazih H, Bard JM. 2020; Cholesterol, oxysterols and LXRs in breast cancer pathophysiology. Int J Mol Sci. 21:1356. DOI: 10.3390/ijms21041356. PMID: 32079340. PMCID: PMC7072989.

27. Uppal H, Zhai Y, Gangopadhyay A, et al. 2008; Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology. 47:1331–1342. DOI: 10.1002/hep.22175. PMID: 18318438.

28. Luu W, Sharpe LJ, Capell-Hattam I, Gelissen IC, Brown AJ. 2016; Oxysterols: Old tale, new twists. Annu Rev Pharmacol Toxicol. 56:447–467. DOI: 10.1146/annurev-pharmtox-010715-103233. PMID: 26738477.

29. Cardoso D, Perucha E. 2021; Cholesterol metabolism: a new molecular switch to control inflammation. Clin Sci (Lond). 135:1389–1408. DOI: 10.1042/CS20201394. PMID: 34086048. PMCID: PMC8187928.

30. Xu H, Zhou S, Tang Q, Xia H, Bi F. 2020; Cholesterol metabolism: New functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 1874:188394. DOI: 10.1016/j.bbcan.2020.188394. PMID: 32698040.

31. Oni TE, Biffi G, Baker LA, et al. 2020; SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. J Exp Med. 217:e20192389. DOI: 10.1084/jem.20192389. PMID: 32633781. PMCID: PMC7478739.

32. Sun H, Li L, Li W, et al. 2021; p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. EMBO Rep. 22:e52537. DOI: 10.15252/embr.202152537. PMID: 34459531. PMCID: PMC8490977.

33. O'Neill KI, Kuo LW, Williams MM, et al. 2022; NPC1 confers metabolic flexibility in triple negative breast cancer. Cancers (Basel). 14:3543. DOI: 10.3390/cancers14143543. PMID: 35884604. PMCID: PMC9319388.

34. Weiss SB, Kennedy EP, Kiyasu JY. 1960; The enzymatic synthesis of triglycerides. J Biol Chem. 235:40–44. DOI: 10.1016/S0021-9258(18)69581-X. PMID: 13843753.

35. Sanders FW, Griffin JL. 2016; De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 91:452–468. DOI: 10.1111/brv.12178. PMID: 25740151. PMCID: PMC4832395.

36. Softic S, Cohen DE, Kahn CR. 2016; Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci. 61:1282–1293. DOI: 10.1007/s10620-016-4054-0. PMID: 26856717. PMCID: PMC4838515.

37. Geidl-Flueck B, Hochuli M, Németh Á, et al. 2021; Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. J Hepatol. 75:46–54. DOI: 10.1016/j.jhep.2021.02.027. PMID: 33684506.

38. Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. 2014; De novo lipogenesis in health and disease. Metabolism. 63:895–902. DOI: 10.1016/j.metabol.2014.04.003. PMID: 24814684.

39. Lee DS, An TH, Kim H, et al. 2023; Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice. Diabetologia. 66:931–954. DOI: 10.1007/s00125-023-05878-8. PMID: 36759348. PMCID: PMC10036287.

40. Zeng H, Qin H, Liao M, et al. 2022; CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. Mol Metab. 57:101428. DOI: 10.1016/j.molmet.2021.101428. PMID: 34974159. PMCID: PMC8810570.

41. Kawano Y, Cohen DE. 2013; Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 48:434–441. DOI: 10.1007/s00535-013-0758-5. PMID: 23397118. PMCID: PMC3633701.

42. Smith U, Kahn BB. 2016; Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 280:465–475. DOI: 10.1111/joim.12540. PMID: 27699898. PMCID: PMC5218584.

43. Zhou B, Luo Y, Ji N, Hu C, Lu Y. 2022; Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nat Metab. 4:1185–1201. DOI: 10.1038/s42255-022-00627-4. PMID: 36050503.

44. Ibarretxe D, Masana L. 2021; Triglyceride metabolism and classification of hypertriglyceridemias. Clin Investig Arterioscler. 33 Suppl 2:1–6. DOI: 10.1016/j.arteri.2021.02.004. PMID: 34006348.

45. Kersten S. 2023; The impact of fasting on adipose tissue metabolism. Biochim Biophys Acta Mol Cell Biol Lipids. 1868:159262. DOI: 10.1016/j.bbalip.2022.159262. PMID: 36521736.

46. Barrows BR, Parks EJ. 2006; Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab. 91:1446–1452. DOI: 10.1210/jc.2005-1709. PMID: 16449340.

47. Cerk IK, Wechselberger L, Oberer M. 2018; Adipose triglyceride lipase regulation: An overview. Curr Protein Pept Sci. 19:221–233. DOI: 10.2174/1389203718666170918160110. PMID: 28925902. PMCID: PMC7613786.

48. Schott MB, Weller SG, Schulze RJ, et al. 2019; Lipid droplet size directs lipolysis and lipophagy catabolism in hepatocytes. J Cell Biol. 218:3320–3335. DOI: 10.1083/jcb.201803153. PMID: 31391210. PMCID: PMC6781454.

49. Fyrst H, Saba JD. 2010; An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 6:489–497. DOI: 10.1038/nchembio.392. PMID: 20559316. PMCID: PMC3001344.

50. Alb JG Jr, Kearns MA, Bankaitis VA. 1996; Phospholipid metabolism and membrane dynamics. Curr Opin Cell Biol. 8:534–541. DOI: 10.1016/S0955-0674(96)80032-9. PMID: 8791444.

51. Moreau P, Cassagne C. 1994; Phospholipid trafficking and membrane biogenesis. Biochim Biophys Acta. 1197:257–290. DOI: 10.1016/0304-4157(94)90010-8. PMID: 7819268.

52. Dickson EJ. 2022; Phosphoinositide transport and metabolism at membrane contact sites. Biochim Biophys Acta Mol Cell Biol Lipids. 1867:159107. DOI: 10.1016/j.bbalip.2021.159107. PMID: 34995791. PMCID: PMC9662651.

53. Fruman DA, Meyers RE, Cantley LC. 1998; Phosphoinositide kinases. Annu Rev Biochem. 67:481–507. DOI: 10.1146/annurev.biochem.67.1.481. PMID: 9759495.

54. McDermott MI, Wang Y, Wakelam MJO, Bankaitis VA. 2020; Mammalian phospholipase D: Function, and therapeutics. Prog Lipid Res. 78:101018. DOI: 10.1016/j.plipres.2019.101018. PMID: 31830503. PMCID: PMC7233427.

55. Dekker N. 2000; Outer-membrane phospholipase A: known structure, unknown biological function. Mol Microbiol. 35:711–717. DOI: 10.1046/j.1365-2958.2000.01775.x. PMID: 10692149.

56. Cartier A, Hla T. 2019; Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 366:eaar5551. DOI: 10.1126/science.aar5551. PMID: 31624181. PMCID: PMC7661103.

57. Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N. Alimentiv Translational Research Consortium (ATRC). 2022; Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 19:351–366. DOI: 10.1038/s41575-021-00574-7. PMID: 35165437.

58. Jozefczuk E, Guzik TJ, Siedlinski M. 2020; Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res. 156:104793. DOI: 10.1016/j.phrs.2020.104793. PMID: 32278039.

59. Obinata H, Hla T. 2019; Sphingosine 1-phosphate and inflammation. Int Immunol. 31:617–625. DOI: 10.1093/intimm/dxz037. PMID: 31049553. PMCID: PMC6939830.

60. Erlinger S. 2012; Low phospholipid-associated cholestasis and cholelithiasis. Clin Res Hepatol Gastroenterol. 36 Suppl 1:S36–40. DOI: 10.1016/S2210-7401(12)70019-0. PMID: 23141892.

61. Wang HH, Portincasa P, Liu M, Wang DQ. 2022; Genetic analysis of ABCB4 mutations and variants related to the pathogenesis and pathophysiology of low phospholipid-associated cholelithiasis. Genes (Basel). 13:1047. DOI: 10.3390/genes13061047. PMID: 35741809. PMCID: PMC9222727.

62. Sam PN, Avery E, Claypool SM. 2019; Proteolytic control of lipid metabolism. ACS Chem Biol. 14:2406–2423. DOI: 10.1021/acschembio.9b00695. PMID: 31503446. PMCID: PMC6989095.

63. Nishimura T, Stefan CJ. 2020; Specialized ER membrane domains for lipid metabolism and transport. Biochim Biophys Acta Mol Cell Biol Lipids. 1865:158492. DOI: 10.1016/j.bbalip.2019.07.001. PMID: 31349025.

64. Coleman R. Bile salts and biliary lipids. Biochem Soc Trans. 1987; 15 Suppl:68S–80S.

65. Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. 2012; Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 3:7–20. DOI: 10.4292/wjgpt.v3.i2.7. PMID: 22577615. PMCID: PMC3348960.

66. Claudel T, Zollner G, Wagner M, Trauner M. 2011; Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta. 1812:867–878. DOI: 10.1016/j.bbadis.2010.12.021. PMID: 21194565.

67. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. 2001; Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci. 46:540–544. DOI: 10.1023/A:1005643014395. PMID: 11318529.

68. Hu H, Shao W, Liu Q, et al. 2022; Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat Commun. 13:252. DOI: 10.1038/s41467-021-27758-8. PMID: 35017486. PMCID: PMC8752841.

69. Yu H. 2022; HDL and scavenger receptor class B type I (SRBI). Adv Exp Med Biol. 1377:79–93. DOI: 10.1007/978-981-19-1592-5_6. PMID: 35575922.

70. Hermann S, Kuhlmann MT, Starsichova A, et al. 2016; Imaging reveals the connection between spontaneous coronary plaque ruptures, atherothrombosis, and myocardial infarctions in HypoE/SRBI-/- Mice. J Nucl Med. 57:1420–1427. DOI: 10.2967/jnumed.115.171132. PMID: 27127225.

71. Miquel JF, Moreno M, Amigo L, et al. 2003; Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium. Gut. 52:1017–1024. DOI: 10.1136/gut.52.7.1017. PMID: 12801960. PMCID: PMC1773711.

72. Rigotti A, Zanlungo S, Miquel JF, Wang DQ. 2002; HDL receptor SR-BI and cholesterol gallstones. Hepatology. 35:240–242. DOI: 10.1053/jhep.2002.30273. PMID: 11786985.

73. Chen L, Qiu W, Sun X, et al. 2024; Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis. Gut. 73:521–532.

74. Xie Y, Cifarelli V, Pietka T, et al. 2017; Cd36 knockout mice are protected against lithogenic diet-induced gallstones. J Lipid Res. 58:1692–1701. DOI: 10.1194/jlr.M077479. PMID: 28634191. PMCID: PMC5538290.

75. Castro J, Amigo L, Miquel JF, et al. 2007; Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology. 45:1261–1266. DOI: 10.1002/hep.21616. PMID: 17464999.

76. Smelt AH. 2010; Triglycerides and gallstone formation. Clin Chim Acta. 411:1625–1631. DOI: 10.1016/j.cca.2010.08.003. PMID: 20699090.

77. Hofmann AF, Schteingart CD, vanSonnenberg E, Esch O, Zakko SF. 1991; Contact dissolution of cholesterol gallstones with organic solvents. Gastroenterol Clin North Am. 20:183–199. DOI: 10.1016/S0889-8553(21)00540-9. PMID: 2022421.

78. Koh EH, Yoon JE, Ko MS, et al. 2021; Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis. Gut. 70:1954–1964. DOI: 10.1136/gutjnl-2020-322509. PMID: 33208407. PMCID: PMC8458090.

79. Chen Y, Cao Y. 2017; The sphingomyelin synthase family: proteins, diseases, and inhibitors. Biol Chem. 398:1319–1325. DOI: 10.1515/hsz-2017-0148. PMID: 28742512.

80. Endo T, Tamura Y, Kawano S. 2018; Phospholipid transfer by ERMES components. Aging (Albany NY). 10:528–529. DOI: 10.18632/aging.101434. PMID: 29706612. PMCID: PMC5940124.

81. Dong C, Condat B, Picon-Coste M, et al. 2020; Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Rep. 3:100201. DOI: 10.1016/j.jhepr.2020.100201. PMID: 33554096. PMCID: PMC7848766.

82. Goubault P, Brunel T, Rode A, Bancel B, Mohkam K, Mabrut JY. 2019; Low-Phospholipid Associated Cholelithiasis (LPAC) syndrome: A synthetic review. J Visc Surg. 156:319–328. DOI: 10.1016/j.jviscsurg.2019.02.006. PMID: 30922600.

83. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. 2009; Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci (Landmark Ed). 14:4242–4256. DOI: 10.2741/3526. PMID: 19273348.

84. Atamanalp SS, Keles MS, Atamanalp RS, Acemoglu H, Laloglu E. 2013; The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration. Pak J Med Sci. 29:187–190. DOI: 10.12669/pjms.291.2798. PMID: 24353537. PMCID: PMC3809189.

85. Fu X, Gong K, Shao X. 1995; The relationship between serum lipids, apolipoproteins level and bile lipids level, chemical type of stone. Zhonghua Yi Xue Za Zhi. 75:656–659. 708

86. Lavoie B, Nausch B, Zane EA, et al. 2012; Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease. Neurogastroenterol Motil. 24:e313–e324. DOI: 10.1111/j.1365-2982.2012.01935.x. PMID: 22621672. PMCID: PMC3378777.

87. Wang HH, Portincasa P, Wang DQ. 2019; Update on the molecular mechanisms underlying the effect of cholecystokinin and cholecystokinin-1 receptor on the formation of cholesterol gallstones. Curr Med Chem. 26:3407–3423. DOI: 10.2174/0929867324666170619104801. PMID: 28625150. PMCID: PMC8118134.

88. Kanto J, Katevuo K. 1981; The effect of drugs with different mechanisms of action on the contraction of the human gallbladder. Int J Clin Pharmacol Ther Toxicol. 19:303–309.

89. Dai X, Shen L. 2022; Advances and trends in omics technology development. Front Med (Lausanne). 9:911861. DOI: 10.3389/fmed.2022.911861. PMID: 35860739. PMCID: PMC9289742.

90. Yamada R, Okada D, Wang J, Basak T, Koyama S. 2021; Interpretation of omics data analyses. J Hum Genet. 66:93–102. DOI: 10.1038/s10038-020-0763-5. PMID: 32385339. PMCID: PMC7728595.

91. Buch S, Schafmayer C, Völzke H, et al. 2007; A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 39:995–999. DOI: 10.1038/ng2101. PMID: 17632509.

92. Yu XH, Qian K, Jiang N, Zheng XL, Cayabyab FS, Tang CK. 2014; ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clin Chim Acta. 428:82–88. DOI: 10.1016/j.cca.2013.11.010. PMID: 24252657.

93. Lauridsen BK, Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. 2015; Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J. 36:1601–1608. DOI: 10.1093/eurheartj/ehv108. PMID: 25841872.

94. Betters JL, Yu L. 2010; NPC1L1 and cholesterol transport. FEBS Lett. 584:2740–2747. DOI: 10.1016/j.febslet.2010.03.030. PMID: 20307540. PMCID: PMC2909875.

95. Cao K, Zhang K, Ma M, Ma J, Tian J, Jin Y. 2021; Lactobacillus mediates the expression of NPC1L1, CYP7A1, and ABCG5 genes to regulate cholesterol. Food Sci Nutr. 9:6882–6891. DOI: 10.1002/fsn3.2600. PMID: 34925816. PMCID: PMC8645708.

96. Li R, Liu Y, Shi J, et al. 2019; Diosgenin regulates cholesterol metabolism in hypercholesterolemic rats by inhibiting NPC1L1 and enhancing ABCG5 and ABCG8. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:1124–1133. DOI: 10.1016/j.bbalip.2019.04.010. PMID: 31054325.

97. Mohammadi A, Bazrafshani MR, Oshaghi EA. 2013; Effect of garlic extract on some serum biochemical parameters and expression of npc1l1, abca1, abcg5 and abcg8 genes in the intestine of hypercholesterolemic mice. Indian J Biochem Biophys. 50:500–504.

98. Gu J, Zhu N, Li HF, et al. 2022; Ezetimibe and cancer: Is there a connection? Front Pharmacol. 13:831657. DOI: 10.3389/fphar.2022.831657. PMID: 35924044. PMCID: PMC9340271.

99. Yang B, Liu B, Bi P, Wu T, Wang Q, Zhang J. 2015; An integrated analysis of differential miRNA and mRNA expressions in human gallstones. Mol Biosyst. 11:1004–1011. DOI: 10.1039/C4MB00741G. PMID: 25639987.

100. Wang G, Zhang H, Zhou Z, et al. 2023; AQP3-mediated activation of the AMPK/SIRT1 signaling pathway curtails gallstone formation in mice by inhibiting inflammatory injury of gallbladder mucosal epithelial cells. Mol Med. 29:116. DOI: 10.1186/s10020-023-00712-8. PMID: 37641009. PMCID: PMC10463418.

101. Guman MSS, Hoozemans JB, Haal S, et al. 2022; Adipose tissue, bile acids, and gut microbiome species associated with gallstones after bariatric surgery. J Lipid Res. 63:100280. DOI: 10.1016/j.jlr.2022.100280. PMID: 36115596. PMCID: PMC9672443.

102. Casertano M, Trotta MC, Cenni S, et al. 2024; Infliximab therapy decreases the expression of serum and faecal miR-126 and miR-20a in paediatric Crohn's disease: A pilot study. Acta Paediatr. 113:590–597. DOI: 10.1111/apa.17072. PMID: 38140840.

103. Wei J, Chen T, Liu Y, et al. 2023; Targeted bile acids metabolomics in cholesterol gallbladder polyps and gallstones: From analytical method development towards application to clinical samples. J Pharm Anal. 13:1080–1087. DOI: 10.1016/j.jpha.2023.06.003. PMID: 37842658. PMCID: PMC10568091.

104. Slyshenkov VS, Rakowska M, Wojtczak L. 1996; Protective effect of pantothenic acid and related compounds against permeabilization of Ehrlich ascites tumour cells by digitonin. Acta Biochim Pol. 43:407–410. DOI: 10.18388/abp.1996_4512. PMID: 8862188.

105. Akram M. 2014; Citric acid cycle and role of its intermediates in metabolism. Cell Biochem Biophys. 68:475–478. DOI: 10.1007/s12013-013-9750-1. PMID: 24068518.